Azithromycin use and outcomes in severe sepsis patients with and without pneumonia

Journal of Critical Care

Volumn 32, Issue , 2016, Pages 120-125

  Afshar, Majid ^a,b   Foster, Clayton L ^c   Layden, Jennifer E ^a,b   Burnham, Ellen L ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Azithromycin; Inflammation; Intensive care unit; Macrolide; Mechanical ventilation; Severe sepsis

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; AGED; COMPLICATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84959495251     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2015.12.010     Document Type: Article

References (39)

1. Restrepo M.I., Mortensen E.M., Waterer G.W., Wunderink R.G., Coalson J.J., Anzueto A., et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009, 33:153-159.
2. Martin-Loeches I., Lisboa T., Rodriguez A., Putensen C., Annane D., Garnacho-Montero J., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36:612-620.
3. Walkey A.J., Wiener R.S. Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012, 141:1153-1159.
4. Brusselle G.G., Vanderstichele C., Jordens P., Deman R., Slabbynck H., Ringoet V., et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013, 68:322-329.
5. Parnham M.J., Culic O., Erakovic V., Munic V., Popovic-Grie S., Barisic K., et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 2005, 517:132-143.
6. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A., Criner G.J., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
7. Southern K.W., Barker P.M., Solis-Moya A., Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012, 11:1-80.
8. Solidoro P., Braido F., Boffini M., Corsico A.G. New life for macrolides. Minerva Med 2013, [Epub ahead of print].
9. Reiter J., Demirel N., Mendy A., Gasana J., Vieira E.R., Colin A.A, et al. Macrolides for the long-term management of asthma-a meta-analysis of randomized clinical trials. Allergy 2013, 68:1040-1049.
10. Parnham M.J. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18:125-131.
11. Giamarellos-Bourboulis E.J. Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents 2008, 32(Suppl. 1):S39-S43.
12. Carlyn C.J., Andersen N.J., Baltch A.L., Smith R., Reilly A.A, Lawrence D.A, et al. Analysis of septic biomarker patterns: prognostic value in predicting septic state. Diagn Microbiol Infect Dis 2015, 83:312-318.
13. Sligl W.I., Asadi L., Eurich D.T., Tjosvold L., Marrie T.J., Majumdar S.R, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014, 42:420-432.
14. Giamarellos-Bourboulis E.J., Mylona V., Antonopoulou A., Tsangaris I., Koutelidakis I., Marioli A., et al. Effect of clarithromycin in patients with suspected gram-negative sepsis: results of a randomized controlled trial. J Antimicrob Chemother 2014, 69:1111-1118.
15. Healy D.P. Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep 2007, 9:7-13.
16. Asadi L., Sligl W.I., Eurich D.T., Colmers I.N., Tjosvold L., Marrie T.J., et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012, 55:371-380.
17. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
18. Ramanathan R., Leavell P., Stockslager G., Mays C., Harvey D., Duane T.M, et al. Validity of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) screening for sepsis in surgical mortalities. Surg Infect (Larchmt) 2014, 15:513-516.
19. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
20. Weisblum B., Davies J. Antibiotic inhibitors of the bacterial ribosome. Bacteriol Rev 1968, 32:493-528.
21. Schoenfeld D.A., Bernard G.R., Network A. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002, 30:1772-1777.
22. Estenssoro E., Gonzalez F., Laffaire E., Canales H., Saenz G., Reina R., et al. Shock on admission day is the best predictor of prolonged mechanical ventilation in the ICU. Chest 2005, 127:598-603.
23. Rodrigo C., McKeever T.M., Woodhead M., Lim W.S. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2013, 68:493-495.
24. Vincent J.L. Endpoints in sepsis trials: more than just 28-day mortality?. Crit Care Med 2004, 32:S209-S213.
25. Kaukonen K.M., Bailey M., Suzuki S., Pilcher D., Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014, 311:1308-1316.
26. Spyridaki A., Raftogiannis M., Antonopoulou A., Tsaganos T., Routsi C., Baziaka F., et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 2012, 56:3819-3825.
27. Wong C., Jayaram L., Karalus N., Eaton T., Tong C., Hockey H., et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
28. Vos R., Vanaudenaerde B.M., Verleden S.E., Ruttens D., Vaneylen A., Van Raemdonck D.E., et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 2012, 94:101-109.
29. Amsden G.W. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 2005, 55:10-21.
30. Leiva M., Ruiz-Bravo A., Jimenez-Valera M. Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest 2008, 134:20-29.
31. Tamaoki J., Kondo M., Kohri K., Aoshiba K., Tagaya E., Nagai A., et al. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 1999, 163:2909-2915.
32. Sato K., Suga M., Akaike T., Fugii S., Muranaka H., Doi T., et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 1998, 157:853-857.
33. Azuma A., Furuta T., Enomoto T., Hashimoto Y., Uematsu K., Nukariya N., et al. Preventive effect of erythromycin on experimental bleomycin-induced acute lung injury in rats. Thorax 1998, 53:186-189.
34. Tamaoki J., Tagaya E., Yamawaki I., Sakai N., Nagai A., Konno K., et al. Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med 1995, 151:1582-1588.
35. Mouncey P.R., Osborn T.M., Power G.S., Harrson D.A, Sadique M.Z., Grieve R.D., et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015, 372:1301-1311.
36. Investigators A., Group A.C.T., Peake S.L., Delaney A., Bailey M., Bellomo R., et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014, 371:1496-1506.
37. Pro C.I., Yealy D.M., Kellum J.A., Huang D.T., Barnato A.E., Weissfeld L.A., et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014, 370:1683-1693.
38. Linde-Zwirble W.T., Angus D.C. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004, 8:222-226.
39. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl. 2):S27-S72.